Rocket Pharmaceuticals Statistics
Rocket Pharmaceuticals (9IP1) Stock Statistics & Valuation Metrics
Total Valuation
Rocket Pharmaceuticals has a market cap or net worth of EUR 242.37M. The enterprise value is EUR 132.69M.
- Market Cap
- EUR 242.37M
- Enterprise Value
- EUR 132.69M
Share Statistics
Rocket Pharmaceuticals has 109,774,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 109,774,600
- Owned by Insiders
- 20.41%
- Owned by Institutions
- 31.85%
Financial Efficiency
Rocket Pharmaceuticals’s return on equity (ROE) is -0.80 and return on invested capital (ROIC) is -75.38%.
- Return on Equity (ROE)
- -0.80
- Return on Assets (ROA)
- -0.68
- Return on Invested Capital (ROIC)
- -75.38%
- Return on Capital Employed (ROCE)
- -0.76
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.10M
- Employee Count
- 202
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Rocket Pharmaceuticals is -15.50. Rocket Pharmaceuticals’s PEG ratio is -0.10.
- PE Ratio
- -15.50
- PS Ratio
- 0.00
- PB Ratio
- 0.76
- Price to FCF
- -1.60
- Price to Operating Cash Flow
- -1.64
- PEG Ratio
- -0.10
Income Statement
In the last 12 months, Rocket Pharmaceuticals had revenue of 0 and earned -223.12M in profits. Earnings per share was -2.01.
- Revenue
- 0
- Gross Profit
- -11.03M
- Operating Income
- -228.52M
- Pretax Income
- -223.12M
- Net Income
- -223.12M
- EBITDA
- -210.21M
- Earnings Per Share (EPS)
- -2.01
Cash Flow
In the last 12 months, operating cash flow was -170.28M and capital expenditures -127,000, giving a free cash flow of -170.40M billion.
- Operating Cash Flow
- -170.28M
- Free Cash Flow
- -170.40M
- Free Cash Flow per Share
- -1.51
Dividends & Yields
Rocket Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -62.59%
- Earnings Yield
- -6.16%
Stock Price Statistics
- Beta
- 1.26
- 52-Week Price Change
- -15.59%
- 50-Day Moving Average
- 2.40
- 200-Day Moving Average
- 2.80
- Relative Strength Index (RSI)
- 49.64
- Average Volume (3m)
- 1,300
Important Dates
Rocket Pharmaceuticals upcoming earnings date is Mar 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 01, 2027
- Ex-Dividend Date
- ―
Financial Position
Rocket Pharmaceuticals as a current ratio of 6.38, with Debt / Equity ratio of 8.97%
- Current Ratio
- 6.38
- Quick Ratio
- 6.38
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.25
- Interest Coverage Ratio
- -120.84
Taxes
In the past 12 months, Rocket Pharmaceuticals has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Rocket Pharmaceuticals EV to EBITDA ratio is 12.49, with an EV/FCF ratio of -0.43.
- EV to Sales
- 0.00
- EV to EBITDA
- 12.49
- EV to Free Cash Flow
- -0.43
- EV to Operating Cash Flow
- -0.43
Balance Sheet
Rocket Pharmaceuticals has EUR 283.75M in cash and marketable securities with EUR 24.80M in debt, giving a net cash position of EUR 258.95M billion.
- Cash & Marketable Securities
- EUR 283.75M
- Total Debt
- EUR 24.80M
- Net Cash
- EUR 258.95M
- Net Cash Per Share
- EUR 2.36
- Tangible Book Value Per Share
- EUR 2.70
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Rocket Pharmaceuticals is EUR 8.51, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 8.51
- Price Target Upside
- 295.62% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 10
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 94.06%
Scores
- Smart Score
- 3
- AI Score
- ―
